OCUMENSION-B (01477) announced its annual performance, with a net loss of 159 million yuan, a decrease of 40.8% year-on-year.

OCUMENSION-B(01477) announced its annual performance for the year ending December 31, 2025. The group achieved revenue of 804 million yuan, an increase of 92.75% compared to the previous year; it incurred a loss of 159 million yuan, a decrease of 40.8% compared to the previous year; the loss per share was 0.2 yuan. The company further expanded its market in hospitals, with sales of its main products showing stable growth. The core product, OptiMate (fluocinolone acetonide intravitreal implant), continued to play a key role in our growth strategy. Beaujeux (apexipetide intravitreal injection) was approved by NMPA for the treatment of adult patients with neovascular (wet) age-related macular degeneration (nAMD) and diabetic macular edema (DME), marking the birth of another important product in the company's field of retinal diseases. The substantial increase in revenue was mainly attributed to a significant increase in sales of ophthalmic products (including Sildar and Eisai Pi as well as products acquired and introduced under the Alcon transaction); and a significant increase in royalty income based on sales, primarily driven by the successful commercialization of Beaujeux.